• Fenipentol: From Natural Product to Assay Design

  2026-08-26

  Fenipentol, also known as 1-Phenyl-1-pentanol, connects volatile natural-product chemistry with secretion, receptor, and metabolism research. This evidence-led guide shows how to translate docking, tissue-resolved metabolomics, and historical physiology findings into better assay decisions.

• Praeruptorin A in Inflammation Models

  2026-08-26

  Praeruptorin A connects STAT-1/3, barrier repair, ferroptosis, and tumor-migration assays in one translational workflow. This guide shows how to select doses, pair phenotype with mechanism, and troubleshoot solvent, timing, and model-specific variability.

• Stromal Homeostasis Nanomedicine in Pancreatic Cancer

  2026-08-25

  Fu et al. developed an acid-responsive, multistage nanomedicine that remodels pancreatic tumor stroma before releasing gemcitabine from an inner mesoporous silica core. In a pancreatic ductal adenocarcinoma mouse model, this sequential strategy produced marked tumor regression without reported overt side effects, supporting stromal reprogramming as an alternative to nonspecific stromal ablation.

• Matrine Workflows for Thymoma and Inflammation

  2026-08-25

  Matrine provides a flexible research starting point for linking cancer-cell viability, stemness, apoptosis, and inflammatory injury assays. This workflow translates recent thymoma findings into practical dose planning, controls, mechanistic validation, and troubleshooting guidance.

• LDN-193189: A Strategic Guide to BMP Signal Control

  2026-08-24

  A translational guide to using LDN-193189 as an ALK inhibitor for causal BMP biology, epithelial barrier studies, and heterotopic ossification research, with practical protocols, evidence boundaries, and strategic guidance beyond conventional product-page claims.

• 4-Phenylbutyric Acid for ER Stress Assays

  2026-08-24

  Use 4-PBA as a reversible chemical-chaperone intervention to test whether ER stress contributes to toxicant-induced injury. In PFOS-challenged HK-2 cells, pairing ER-stress markers with ferroptosis endpoints helps distinguish pathway rescue from nonspecific cytoprotection.

• SB525334 Workflows for TGF-beta1 Signaling

  2026-08-23

  Use SB525334 as a selective ALK5 perturbation tool to connect Smad2/3 signaling with profibrotic gene expression, renal injury, and chronic-wound repair. This workflow emphasizes concentration control, orthogonal readouts, and careful translation of diabetic foot ulcer findings into fibrosis research.

• Triamcinolone B1859: Practical Research Guide

  2026-08-22

  Triamcinolone B1859 provides a defined synthetic glucocorticoid agonist for controlled studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This dossier-led guidance addresses preparation, storage, assay controls, and troubleshooting; the compound is for scientific research only and should not be used diagnostically, therapeutically, or clinically.

• Hypoxia, Choroid Plexus, and Cognitive Impairment

  2026-08-22

  This mouse study identifies choroid plexus barrier disruption and M1 macrophage polarization as central links between simulated high-altitude hypoxia and cognitive dysfunction. Its main contribution is a mechanistic cascade connecting aberrant AMPK signaling and oxidative stress to neuroimmune barrier failure, providing a framework for studying hypoxia-related CNS injury without reducing the problem to neuronal metabolism alone.

• Mubritinib–HSA Binding: Mechanistic Evidence

  2026-08-21

  The 2023 reference study combines multispectroscopic analysis, biochemical testing, and molecular docking to define how mubritinib binds human serum albumin. Its findings connect moderate, site-I binding with fluorescence, structural, and esterase-like functional changes that may influence mubritinib disposition and pharmacological interpretation.

• NLRP3-Driven Astrocyte States in Morphine Tolerance

  2026-08-20

  The 2024 Frontiers in Pharmacology study links NLRP3 inflammasome activation with a shift in spinal astrocytes toward an A1-like reactive phenotype during morphine tolerance. Its intrathecal morphine model and MCC950 intervention suggest that inflammasome-associated astrocyte remodeling is a modifiable component of opioid tolerance, while leaving cell-specific causality and clinical transferability open for further study.

• Resveratrol, Smad Signaling, and GBM Invasion

  2026-08-20

  The reference study shows that resveratrol suppresses TGF-β1-induced epithelial–mesenchymal transition, migration, invasion, and stem-like properties in glioblastoma models through Smad-dependent signaling. Its integrated use of molecular, functional, stemness, and xenograft assays provides a framework for linking TGF-β pathway activity with invasive behavior, while also highlighting the limits of translating a natural-compound response into clinical therapy.

• Extracellular Vesicle Inhibition in TNBC

  2026-08-19

  McNamee and colleagues systematically tested pharmacological strategies for suppressing extracellular vesicle release from triple-negative breast cancer cells. Their results indicate that multiple EV subpopulations contribute to aggressive cell-to-cell signaling and that substantial, rather than partial, release inhibition may be required to limit functional effects on recipient cells.

• WNT Signaling in Obstructed Extrahepatic Bile Ducts

  2026-08-19

  Calder and colleagues show that WNT signaling is an active component of the extrahepatic bile duct response to obstruction, rather than a pathway restricted to developmental biology or intrahepatic injury. Using bile duct ligation, organoids, explants, pharmacologic perturbation, and transcriptomics, the study links cholangiocyte-derived WNT ligands, β-catenin activity, and proliferative repair.

• Cyclosporin A as a Translational Mechanism Probe

  2026-08-18

  Cyclosporin A is more than a classic immunosuppressant: it is a pathway-resolved probe spanning cyclophilin–calcineurin–NF-AT signaling, p38 MAPK activity, and mitochondrial permeability transition. This thought-leadership guide shows how translational researchers can use Cyclosporin to distinguish target engagement from downstream phenotype while avoiding overinterpretation across immunology, mitochondrial biology, and neuroscience.

8381 records 1/559 page Next 12345 下5页 Last page